Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q1 2024 Earnings Call Transcript
Kiniksa Pharmaceuticals, Ltd. beats earnings expectations. Reported EPS is $-0.00025, expectations were $-0.14.
Kiniksa Pharmaceuticals Ltd. (KNSA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Rubric Capital Management David Rosen | 2,907,501 | $50,997,568 | -6% | 1.05% |
| 2. | Baker Bros. Advisors Julian Baker And Felix Baker | 2,809,577 | $49,279,981 | 0.56% | |
| 3. | Driehaus Capital Richard Driehaus | 661,715 | $11,606,481 | +32% | 0.13% |
| 4. | Parkman Healthcare Partners Greg Martinez | 615,693 | $10,799,255 | +21% | 1.52% |
| 5. | Tang Capital Management Kevin C. Tang | 600,000 | $10,524,000 | 0.97% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $19.24 | 235,019 | Large Shareholder, Other | 843,352 | 2018-05-29 | Filing | |
| $20.91 | 25,000 | Large Shareholder, Other | 608,333 | 2018-05-29 | Filing | |
| $19.81 | 250,000 | Large Shareholder, Other | 583,333 | 2018-05-29 | Filing | |
| $18.00 | 333,333 | Large Shareholder, Other | 333,333 | 2018-05-29 | Filing | |
| $18.00 | 69,444 | Large Shareholder | 900,443 | 2018-05-29 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $21.02 | 65,012 | 0 | 2024-03-07 | Filing | ||
| $21.00 | 5,582 | 65,012 | 2024-03-06 | Filing | ||
| $22.00 | 3,336 | 70,594 | 2024-03-04 | Filing | ||
| $21.31 | 9,406 | 73,930 | 2024-03-04 | Filing | ||
| $22.03 | 1,189 | 122,847 | 2024-03-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,180,588 | $55,787,514 | 0% | |
| 2. | 2,965,299 | $52,011,344 | 0% | |
| 3. | 2,883,221 | $50,571,696 | 5.34% | |
| 4. | 1,595,479 | $27,984,701 | 0% | |
| 5. | 1,570,816 | $27,552,113 | 0.03% |
News See All
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Kiniksa Pharmaceuticals Fourth Quarter and Full Year 2023 Earnings Conference Call.
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q3 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Kiniksa Pharmaceuticals Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
12 Cheap Biotech Stocks Smart Investors Are Piling Into
In this piece, we will take a look at 12 cheap biotechnology stocks that smart investors are piling into.
25 Biggest Stocks with Negative Beta
Stock markets were in see-saw mode before the Fed’s September decision on rate hikes.
13 NASDAQ Stocks with Lowest PE Ratios That May Not Be Value Traps
In this piece, we will take a look at the 13 NASDAQ stocks with lowest PE ratios. If you want to skip our primer on one of the best performing U.S.
11 Most Undervalued Biotech Stocks to Buy According to Analysts
In this article, we will take a look at the 11 most undervalued biotech stocks to buy according to analysts.
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q2 2023 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Kiniksa Pharmaceuticals Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q1 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by and welcome to the Kiniksa Pharmaceuticals First Quarter 2023 Earnings Conference Call.
12 Cheap Healthcare Stocks to Buy in 2023
The healthcare sector is one of the few industries that has rapidly transformed itself in just a couple of decades.
Billionaire Hedge Funds
